Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization

EunJu Cho1,*, Hyo-Cheol Kim2,*, Jeong-Hoon Lee3,*, Jeong-ju Yoo3, Won-Mook Choi3, Young Youn Cho3, Min Jong Lee3, Yuri Cho3, Dong Hyeon Lee3, Yun Bin Lee3, Su Jong Yu3, Yoon Jun Kim3, Jung-Hwan Yoon3, Jin Wook Chung3, Chung Yong Kim3, Hyo-Suk Lee3

1 Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea, 2 Department of Radiology, Seoul National University College of Medicine, Seoul, Korea, 3 Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

Abstract

Insulin-like growth factor-1 (IGF-1) reflects hepatic synthetic function and plays a major role in the development and progression of various cancers. In the present study, we investigated whether baseline serum IGF-1 levels predict time-to-progression (TTP) and overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). A total of 155 consecutive treatment-naïve patients with HCC who had undergone TACE as initial treatment were included from a prospective cohort. Baseline serum IGF-1 levels were analyzed with regard to their associations with disease progression and survival. During a median follow-up period of 41.8 months, patients with low IGF-1 levels showed significantly shorter TTP (median, 6.0 months; 95% confidence interval [CI], 4.5–7.6) than patients with high IGF-1 levels (median, 16.5 months; 95% CI, 4.9–28.1; p = 0.003). In the multivariate analysis, BCLC stage, serum vascular endothelial growth factor levels, and IGF-1 levels were independent risk factors for disease progression. The hazard ratio (HR) of progression for each 10 ng/mL decrease in IGF-1 level was 1.072 (95% CI, 1.029–1.117; p = 0.001). Furthermore, together with tumor size, stage, and treatment response, IGF-1 levels were an independent predictor of poorer survival (for each 10 ng/mL decrease in IGF-1 level; HR, 1.057; 95% CI, 1.001–1.115; p = 0.045). In conclusion, low baseline IGF-1 levels independently correlated with shorter TTP and poorer OS in patients with HCC who underwent TACE.

Introduction

Hepatocellular carcinoma (HCC) is a hypervascular tumor, and angiogenesis induced by angiogenic factors, such as vascular endothelial growth factor (VEGF), plays a pivotal role in tumor growth, invasion, and metastasis [1]. This characteristic made transarterial chemoembolization (TACE) a main treatment for nonsurgical patients with large, multifocal tumor [2–4]. However, the long-term prognosis is still poor because of the high frequency of disease progression, although initial remission is achieved by TACE. Therefore, the identification of risk factors for tumor progression after TACE is important for selecting appropriate therapies and predicting a prognosis.

Insulin-like growth factor-1 (IGF-1) is a potent survival factor and implicated in the development and progression of various cancers [5]. The stimulatory ligand and its receptors are overexpressed in many cancer cells and induce cell survival, proliferation, and angiogenesis. Additionally, IGF-1 has been shown to synergize with tissue hypoxia to enhance tumor growth and metastasis [6,7]. Moreover, epidemiologic studies have shown an association between high circulating IGF-1 levels and an increased risk of prostate, breast, and colon cancer [8,9]. However, the relevance IGF-1 system to HCC is somewhat different from other malignancies. Because the majority of circulating IGF-1 is produced by the liver, IGF-1 levels reflect hepatic function and are inversely correlated with the severity of background chronic liver disease [10,11]. Moreover, recent study has shown that a decrease in serum IGF-1 levels is associated with the development of HCC, regardless of the grade of hepatic dysfunction [12]. Low serum IGF-1 levels were also associated with a poor response to antiangiogenic therapy, leading to an unfavorable prognosis in patients with advanced HCC [13]. In addition, we recently found that low baseline serum IGF-1 levels were independently associated with a shorter time to recurrence and poorer OS in patients who received curative therapy for early-stage HCC [14].

Citation: Cho E, Kim H-C, Lee J-H, Yoo J-j, Choi W-M, et al. (2014) Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. PLoS ONE 9(3): e90862. doi:10.1371/journal.pone.0090862

Editor: Lian-Yue Yang, Xiangya Hospital of Central South University, China

Received November 16, 2013; Accepted February 5, 2014; Published March 4, 2014

Copyright: © 2014 Cho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-000-7381) and Kangwon National University Hospital Grant (2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: pindra@empal.com

† These authors contributed equally to this work.
Collectively, these findings suggest that IGF-1 levels may be associated with the extent of disease, treatment response, and prognosis. However, this assumption has not been tested in patients with HCC who have undergone TACE. Thus, the present study evaluated whether basal serum IGF-1 levels can predict prognosis of HCC patients according to different risks of disease progression and death after TACE.

Materials and Methods

Study Population

The present study was part of an ongoing prospective cohort study identifying the biomarkers associated with treatment response and prognosis in HCC at Seoul National University Hospital (Seoul, Republic of Korea). Between January 2006 and July 2010, 198 treatment-naïve patients with HCC who had undergone TACE as initial treatment were enrolled in this study. The diagnosis of HCC was made according to the recommendations of the American Association for the Study of Liver Diseases [4]. The indication of TACE was mainly non-surgical patients with large/multifocal HCC, but patients with early-stage HCC who were unsuitable for surgical resection or ablation because of liver function, comorbidity, or technical infeasibility also received TACE. Among the enrolled patients, we excluded 43 patients because of extrathepatic metastasis (n = 5), no measurable target lesions (infiltrative pattern, or largest lesion less than 1 cm) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [15] (n = 35), and early follow-up loss after first-session TACE (n = 3). The remaining 155 patients were included in the study.

The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital. All of the participants provided written informed consent.

TACE Procedure

Details of the procedure performed in our institution have been described previously [16]. Briefly, a solution that contained 10–60 mg of doxorubicin hydrochloride emulsion (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Korea) and 2–12 mL of ethiodized oil (Lipiodol; Andre Guerbet, Aulnay-sous-Bois, France) was infused through a microcatheter (Microferret; Cook, Bloomington, IN, or Progreat; Terumo, Tokyo, Japan) until arterial flow stasis was achieved and/or ethiodized oil appeared in the portal branches. Subsequently, embolization was performed with absorbable gelatin sponge particles 1 mm in diameter (Gelfoam; Upjohn, Kalamazoo, MI, or Cutanplast/MasciaBrunelli, Milano, Italy) soaked in a mixture of 10–20 mg doxorubicin hydrochloride and 10 mL of nonionic contrast medium.

Contrast-enhanced dynamic computed tomography (CT) was performed 4 weeks after TACE to assess the need of a consecutive treatment. Because mRECIST could not reliably predict the prognosis of HCC patients undergoing TACE as initial treatment [17–19], we assessed overall response at the initial TACE using mRECIST criteria. The patients with objective response (defined as complete or partial response) were classified as responders and the others were classified as non-responders. Repeated TACE was performed every 6–12 weeks if viable tumors (i.e., contrast material uptake in the arterial phase and washout in the portal and/or late venous phase) were detected on sequential imaging without deterioration of liver function.

Measurement of Serum IGF-1 and VEGF

Peripheral blood samples were collected before the first treatment. Serum samples were aliquoted and stored at −80°C. Serum IGF-1 levels were quantified using an immunoradiometric assay with standard commercial kits (Immunotech, Marseille, France). VEGF levels were measured using a Luminex 200 (Millipore, Billerica, MA) and Bio-PlexTM Reagent Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s instructions.

Outcomes and Assessments

The primary endpoint of the study was time-to-progression (TTP), measured from the date of enrollment until the first documented tumor progression in imaging studies according to the mRECIST. The secondary endpoint was OS, defined as time from enrollment to death.

Statistical Analyses

Continuous variables are presented as medians and interquartile ranges (IQRs) or means and standard deviations (SDs). The Mann-Whitney U test and Kruskal-Wallis test were used to analyze differences between the different groups. The χ² test or Fisher’s exact test was used for categorical data. Pearson’s and Spearman’s correlation coefficients (r and ρ, respectively) were used to evaluate the relationships between clinical characteristics and the levels of IGF-1 and VEGF. Time-dependent receiver-operating characteristic (ROC) curves for censored survival data were constructed to define the best cut-off value for predicting outcome [20]. The best cut-off was defined as the value with the maximal sum of sensitivity and specificity [21]. Confidence intervals (CI) for the area under the ROC curve (AUC) were obtained from 1,000 bootstrapped samples. Survival curves were compared using the log-rank test and Breslow test. Cox proportional hazard regression analysis was performed to evaluate independent risk factors for disease progression and OS. Variables with P<0.05 in the univariate Cox regression analysis were subjected to multivariate analysis using forward stepwise selection. Differences at P<0.05 were considered statistically significant. The analyses were performed using SPSS 19.0 K (SPSS, Chicago, IL) and the R statistical programming environment, Version 3.0.1 (http://www.r-project.org).

Results

Baseline Patient Characteristics and Treatment Outcomes

The baseline characteristics of the study population are summarized in Table 1. Of the 155 patients, 126 (81.3%) were male. The median age at the time of diagnosis was 56 years (IQR, 50–64 years). Hepatitis B virus infection was the most common cause of underlying liver disease (76.8%), and most (85.8%) of the patients had preserved Child-Pugh class A liver function. The median size of the largest measurable lesion was 3.8 cm (IQR, 2.1–7.0 cm). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, 10, 63, 44, and 38 patients belonged to stage 0, A, B, and C, respectively. The median number of TACE procedures was 4 (IQR, 2–7).

During a median follow-up period of 41.8 months (IQR, 16.3–67.1 months), 132 patients (85.2%) experienced disease progression. The overall cumulative progression rate in HCC patients following TACE was 68.8% after 1 year, 83.0% after 2 years, and 87.9% after 3 years. The median time-to-progression (TTP) and median progression-free survival (PFS) were both 6.7 months (95% confidence interval [CI], 5.0–8.4). The overall cumulative death rate was 21.4% after 1 year, 32.6% after 2 years, and 42.0% after 5 years. The median OS was not reached (71 of 155 patients died).
The associations between clinical factors and the levels of IGF-1 and VEGF are described in Table 1. The levels of IGF-1 decreased in patients with Child-Pugh class B \((P = 0.001)\), whereas they were not significantly different according to age, gender, and etiologies of underlying liver disease. With respect to tumor factors, IGF-1 levels as a continuous levels were not significantly correlated with maximum tumor size and serum \(a\)-fetoprotein (AFP) levels, but showed a negative correlation with tumor number \((r = -0.206, P = 0.01)\). Additionally, the levels of IGF-1

|                          | Patients \((n=155)\) | IGF-1 (ng/mL) | VEGF (ng/mL) |
|--------------------------|----------------------|---------------|--------------|
|                          | Median (IQR)² | \(P\) | Median (IQR)² | \(P\) |
| Age (years)              |                      |               |              |
| <60                      | 90 (58.1) | 94.5 (52.8–125.5) | 29.13 (159.7–524.8) |
| ≥60                      | 65 (41.9) | 88.0 (52.5–122.5) | 263.9 (150.7–505.6) |
| Gender                   | 0.813                | 0.579            |
| Female                   | 29 (18.7) | 89.0 (57.5–118.0) | 326.3 (150.7–600.6) |
| Male                     | 126 (81.3) | 91.0 (51.3–127.8) | 279.3 (158.9–465.9) |
| Hepatitis infection status¹ | 0.293                | 0.842            |
| HBsAg positive           | 119 (76.8) | 96.0 (54.0–130.0) | 271.3 (157.1–448.4) |
| Anti–HCV positive        | 19 (12.3) | 72.0 (43.0–106.0) | 285.1 (140.6–622.2) |
| NBNC                     | 17 (11.0) | 91.0 (51.0–108.5) | 301.7 (152.7–554.5) |
| Clinical cirrhosis³      | 0.104                | 0.087            |
| Present                  | 142 (91.6) | 88.0 (52.8–120.3) | 268.9 (153.7–485.6) |
| Absent                   | 13 (8.4)  | 112.0 (68.0–145.0) | 519.3 (252.6–881.9) |
| Child-Pugh class         | <0.001               |              |
| A                        | 133 (85.8) | 99.0 (62.0–131.5) | 286.0 (159.7–524.8) |
| B                        | 22 (14.2)  | 49.0 (20.5–71.8)  | 232.2 (117.5–470.6) |
| Serum AFP (ng/mL)        | 0.829                | 0.232            |
| <200                     | 84 (54.2) | 88.0 (53.2–124.0) | 254.6 (157.9–420.5) |
| ≥200                     | 71 (45.8) | 97.0 (49.0–125.0) | 324.4 (152.8–559.0) |
| AJCC tumor stage⁴        | 0.022                | 0.001            |
| T1                       | 53 (34.2) | 99.0 (65.5–150.0) | 275.2 (144.2–466.1) |
| T2                       | 65 (41.9) | 88.0 (54.0–132.5) | 235.8 (123.8–416.4) |
| T3                       | 37 (23.9) | 71.0 (40.5–106.5) | 415.6 (246.6–799.6) |
| BCLC stage               | 0.010                | <0.001           |
| 0                        | 10 (6.5)  | 78.0 (27.0–96.0)  | 247.7 (98.4–702.0) |
| A                        | 63 (40.6) | 103.0 (65.8–148.8) | 240.4 (142.0–335.1) |
| B                        | 44 (28.4) | 74.5 (53.3–111.3) | 249.8 (134.9–428.1) |
| C                        | 38 (24.5) | 94.5 (41.3–109.6) | 423.0 (286.8–735.0) |
| CLIP                     | 0.283                | 0.003            |
| 0                        | 32 (20.6) | 94.5 (65.3–150.5) | 275.2 (161.1–486.0) |
| 1                        | 66 (42.6) | 96.5 (56.5–136.8) | 235.8 (141.8–388.2) |
| 2                        | 32 (20.6) | 84.5 (50.3–110.5) | 289.8 (123.7–505.6) |
| 3                        | 18 (11.6) | 78.5 (41.0–112.8) | 423.0 (273.7–838.2) |
| 4                        | 7 (4.5)   | 47.0 (32.0–109.0) | 700.1 (383.4–950.2) |
| Okuda stage              | 0.001                | 0.003            |
| 1                        | 126 (81.3) | 97.5 (62.0–131.3) | 258.9 (151.4–435.2) |
| 2                        | 29 (18.7)  | 48.0 (27.0–103.0) | 514.5 (246.2–809.2) |

¹Data are numbers of patients. Numbers in parentheses are percentages.
²Data are median values, with the interquartile range (IQR) in parentheses.
³Clinical cirrhosis was defined as having either one of the following: (i) presence of cirrhosis-related complications including ascites, varices, encephalopathy and/or (ii) radiographic evidence of small-sized or nodular liver with or without splenomegaly.
⁴According to American Joint Committee on Cancer staging system (7th edition, 2010).
AFP = \(a\)-fetoprotein, BCLC = Barcelona Clinic Liver Cancer, CLIP = Cancer of the Liver Italian Program, HBsAg = hepatitis B surface antigen, HCV = hepatitis C virus, NBNC = HBsAg- and anti-hepatitis C virus-negative. 

doi:10.1371/journal.pone.0090862.t001
showed a trend toward a decrease with advancing tumor stage, determined by the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging ($P = 0.218$, $P = 0.01$) and Okuda ($P = 0.273$, $P = 0.001$). Consistent with previous reports [22,23], serum VEGF levels showed a positive correlation with tumor size ($r = 0.430$, $P < 0.001$) and stage determined by various systems, such as the AJCC TNM ($r = 0.202$, $P = 0.02$), BCLC ($r = 0.315$, $P = 0.001$), the Cancer of the Liver Italian Program (CLIP) score ($r = 0.208$, $P = 0.02$) and Okuda ($r = 0.260$, $P = 0.002$).

**Serum IGF-1 Levels as an Independent Prognostic Factor for HCC Progression and Survival**

IGF-1 was initially analyzed for its prognostic value as a continuous variable. Univariate Cox analyses showed that high Child-Pugh score, larger tumor size ($\geq 5$ cm), multiple tumors (i.e., $> 1$), presence of portal vein thrombosis (PVT), advanced BCLC stage, increasing levels of VEGF, and decreasing levels of IGF-1 were significantly associated with shorter TTP (Table 2). Patients with high serum AFP levels ($\geq 200$ ng/mL) showed a trend toward shorter TTP compared with patients with low AFP levels ($< 200$ ng/mL), but the difference was not significant ($P = 0.08$). No significant differences were found according to age or gender. In the multivariate analysis, BCLC stage, IGF-1 levels, and VEGF levels were independent risk factors for disease progression. The hazard ratio (HR) of progression for a 10-point decrease in IGF-1 level was 1.072 (95% CI, 1.029–1.117; $P = 0.001$), and the HR for a 10-point increase in VEGF level was 1.006 (95% CI, 1.002–1.010; $P = 0.003$). Time-dependent ROC analysis showed that the optimal cut-off value for predicting progression within 2 years was 125 ng/mL for IGF-1 (sensitivity, 80.7%; specificity, 45.9%; AUC, 0.63; 95% CI, 0.52–0.75), and 140 pg/mL for VEGF (sensitivity, 83.2%; specificity, 31.6%; AUC, 0.57; 95% CI, 0.46–0.68), respectively. Kaplan-Meier curves for TTP are shown in Fig. 1a. Patients with low IGF-1 levels ($< 125$ ng/mL) showed a significantly shorter TTP (median, 6.0 months; 95% CI, 4.5–7.6) than patients with high IGF-1 levels ($\geq 125$ ng/mL; median, 16.5 months; 95% CI, 4.9–29.1; $P = 0.003$). The cumulative rates of progression at 1, 2, and 3 years were 73.3%, 87.3%, and 91.6%, respectively, in patients with low IGF-1 levels and 48.8%, 65.0%, and 71.4%, respectively, in patients with high IGF-1 levels. Together with Child-Pugh score, BCLC stage, and high levels of VEGF ($\geq 140$ pg/mL), low levels of IGF-1 remained an independent predictor of disease progression (HR, 1.785; 95% CI, 1.050–3.034; $P = 0.03$) in multivariate analysis.

The levels of IGF-1 were also significantly associated with OS. In the multivariate analysis, IGF-1 levels, BCLC stage, larger tumor size, and mRECIST non-responders were independent risk factors for poorer OS (Table 3). The HR of death for a 10-point decrease in IGF-1 level was 1.071 (95% CI, 1.029–1.117; $P = 0.001$), and the HR for a 10-point increase in VEGF level was 1.006 (95% CI, 1.002–1.010; $P = 0.003$). Time-dependent ROC analysis showed that the optimal cut-off value for predicting 5-year survival (sensitivity, 39.6%; specificity, 79.2%; AUC, 0.59; 95% CI, 0.48–0.67) was 125 ng/mL for IGF-1 (sensitivity, 80.7%; specificity, 45.9%; AUC, 0.63; 95% CI, 0.52–0.75), and 140 pg/mL for VEGF (sensitivity, 83.2%; specificity, 31.6%; AUC, 0.57; 95% CI, 0.46–0.68), respectively. Kaplan-Meier curves for OS are shown in Fig. 1b. Patients with low IGF-1 levels ($< 125$ ng/mL) showed a trend toward a decrease with advancing tumor stage, but the difference was not significant ($P = 0.08$). No significant differences were found according to age or gender. In the multivariate analysis, IGF-1 levels lower than 56 ng/mL remained a significant risk factor for poorer OS (HR, 1.889; 95% CI, 1.128–3.163; $P = 0.02$), together with BCLC stage, larger tumor size, and mRECIST non-responders.

**Discussion**

The present study showed that decreasing levels of baseline serum IGF-1 were associated with higher progression rates as well as poorer OS in HCC patients who underwent TACE. The associations were independent of other well-known prognostic factors, including Child-Pugh score, serum AFP level, tumor size and number, stage, and baseline serum VEGF level.

The result that low serum IGF-1 levels were associated with poor prognosis appears to be paradoxical because high IGF-1 levels and subsequent activation of the IGF system have been known as relevant signaling alterations in various cancers [5]. Nonetheless, our results maintain consistency with previous studies of the levels of circulating IGF-1 and prognosis in HCC patients. Kasbe et al. showed that patients with low IGF-1 levels were more likely to exhibit advanced pathologic parameters of HCC, such as multinodularity, large tumor size, and vascular invasion, and had shorter OS [24,25]. Similarly, low baseline serum IGF-1 levels were associated with poor treatment response, PFS, and OS in patients who received anti-angiogenic therapy for advanced HCC [13] and those who underwent curative treatment for early-stage HCC [14]. The present study found that low basal IGF-1 levels were associated with advanced HCC, such as multiple tumors and advanced stage, and low IGF-1 levels predicted shorter TTP and OS in patients treated with TACE. Collectively, these findings suggest that the association between low circulating IGF-1 and unfavorable outcome may remain consistent across various stages of HCC and treatment modalities, and the oncogenic effects of circulating IGF-1 may not play a determinant role in the progression of HCC. However, the possibility that the autocrine/paracrine effects of IGF-1 may be more important than the systemic effects on HCC cannot be excluded.

The decrease of circulating IGF-1 in patients with cirrhosis or HCC has been attributed to a result of liver damage because hepatocytes are the main contributors of IGF-1 [12]. The findings that serum IGF-1 levels in patients with chronic hepatitis C negatively correlated with histologic fibrosis score and improved during anti-viral therapy may support this hypothesis [10]. Moreover, recent studies showed that IGF-1 replacement or gene transfer therapy induced cytoprotective and anti-inflammatory effects leading to improvement of hepatic fibrosis in cirrhotic rats [26,27], and IGF-1 treatment improved serum albumin levels in patients with cirrhosis [28]. These findings simply that low IGF-1 level is not only a result of liver damage, but may also be a contributor to the development of cirrhotic features by promoting pro-inflammatory and profibrogenic responses. Because inflammatory microenvironmental advanced hepatic fibrosis/cirrhosis is important in hepatocarcinogenesis [29–31], these may contribute to the higher recurrence rates in patients with low IGF-1 levels, although the hypothesis could not be directly tested in the present study because histological data were unavailable. Despite most of the patients in our study had preserved Child-Pugh class A liver function, the levels of IGF-1 were still useful predictors of progression and death, independent of remnant liver function. Therefore, the levels of serum IGF-1, expressed as continuous value, may be helpful for accurately assessing hepatic function and the prognostic stratification of patients with HCC in combination with traditional stepwise parameters, such as Child-Pugh class or BCLC stage.

The present study has some limitations. First, the study was performed at a single institution, and the cut-off level of IGF-1...
that was used to divide the patient population was different from previous cohort studies [13,25]. The difference may be attributable to several factors, including different ethnicity (i.e., Asians), a relatively low proportion of patients with chronic hepatitis C in our cohort, and different purposes and methods for cut-off determination. However, when analyzed as a continuous value, IGF-1 level was significantly associated with disease progression and patient survival. Thus, its prognostic value appears to be consistent, regardless of the difference in the cut-off values. Further studies will be needed to develop multi-stage stratification that can discriminate subgroups with different prognoses. Second, the proportion of patients with very-early- or  

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
| Age (≥60 vs. <60 years)                      | 0.758               | 0.536–1.070 0.115     |
| Gender (male vs. female)                     | 1.145               | 0.736–1.783 0.548     |
| Hepatitis virus infection (NBNC vs HBV, HCV) | 0.716               | 1.000                 |
| Child-Pugh score                             | 1.431               | 1.217–1.684 <0.001    |
| AFP (≥200 vs. <200 ng/mL)                    | 1.350               | 0.959–1.900 0.086     |
| Tumor size (≥5 vs. ≤5 cm)                    | 2.421               | 1.699–3.452 <0.001    |
| Tumor number (multifocal vs. unifocal)       | 1.835               | 1.289–2.613 0.001     |
| Presence of PVT                              | 3.399               | 2.127–5.432 <0.001    |
| BCLC stage                                   | <0.001              | 1.000                 |
| 0                                            | 1.000               | 1.000                 |
| A                                            | 2.331               | 0.996–5.457 3.117     |
| B                                            | 3.946               | 1.662–9.372 5.172     |
| C                                            | 13.748              | 5.581–33.865 22.299   |
| Serum IGF-1 (ng/mL)                          | 0.995               | 0.992–0.999 0.007     |
| Serum VEGF (pg/mL)                           | 1.001               | 1.000–1.001 0.002     |

The hazard ratio was calculated by using the Cox proportional hazard model. AFP = α-fetoprotein, BCLC = Barcelona Clinic Liver Cancer, HBV = hepatitis B virus, HCV = hepatitis C virus, NBNC = HBsAg- and ant-hepatitis C virus-negative, PVT = portal vein thrombosis.

doi:10.1371/journal.pone.0090862.t002

Figure 1. Graphs show Kaplan-Meier estimates of (a) time-to-progression and (b) overall survival in HCC patients after transarterial chemoembolization according the levels of baseline serum IGF-1. A cut-off value of 125 ng/mL was used, and P values were derived by log-rank test.

doi:10.1371/journal.pone.0090862.g001
early-stage HCC was relatively high. Therefore, our study may lack a representative sampling of patients with intermediate-to-advanced HCC, the standard target of TACE. However, the focus of our study was to evaluate the prognostic value of IGF-1 in overall HCC patients who were initially treated by TACE. Therefore, we did not exclude patients with very-early- or early-stage HCC who were unsuitable for curative therapies and thereby underwent TACE. Third, the influence of IGF-1 on OS was not fully investigated because of the relatively short follow-up period and small number of events. Further follow-up of our cohort will clarify this association.

In conclusion, the present prospective study found a significant association between serum IGF-1 levels and treatment outcome in HCC patients who underwent TACE. Thus, serum IGF-1 levels may serve as an indicator of liver function and prognostic marker that reflects TTP and OS in HCC patients, which will be helpful for the precise risk stratification of patients.

### References

1. Zhu AX, Duda DG, Sahani DV and Jain RK (2011) HCC and angiogenesis: possible targets and future directions. Nature reviews Clinical oncology 8: 292–301.
2. Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, et al. (2002) Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 20: 4459–4465.
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734–1739.
4. Bruix J, Sherman M and American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020–1022.
5. Maki RG (2010) Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 28: 4965–4995.
6. Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, et al. (2006) Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I. Clin Cancer Res 12: 4506–4514.
7. Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer research 62: 1030–1035.
8. Chan JM, Stampler MJ, Giovannucci E, Gann PH, Ma J, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566.
9. Key TJ, Appleby PN, Reeves GK and Roddam AW (2010) Insulin-like growth factor I (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. The lancet oncology 11: 530–542.
10. Lorenzo-Zuniga V, Bartoli R, Masnou H, Montoliu S, Morillas RM, et al. (2007) Serum concentrations of insulin-like growth factor-I (IGF-I), IGF binding protein 3 (IGFBP3), and breast cancer risk pooled individual data analysis of 17 prospective studies. The lancet oncology 11: 530–542.
11. Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, et al. (2008) Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 49: 34–42.

### Table 3. Univariate and multivariate analyses of factors associated with overall survival.

| Variable          | Univariate analysis |          |          |          |          |          |          |          |
|-------------------|---------------------|----------|----------|----------|----------|----------|----------|----------|
|                    | Hazard ratio        | 95% CI   | P Value  | Hazard ratio | 95% CI   | P Value  |
| Age (≥60 vs. <60 years) | 0.875              | 0.582–1.316 | 0.522    |          |          |          |
| Gender (male vs. female) | 0.824              | 0.503–1.350 | 0.443    |          |          |          |
| Hepatitis virus infection |                  |          |          | 0.601    |          |          |
| HBV               | 1.339              | 0.671–2.672 |          |          |          |          |
| HCV               | 1.070              | 0.435–2.633 |          |          |          |          |
| Child-Pugh score  | 1.363              | 1.151–1.614 | <0.001   |          |          | 0.759    |
| AFP (<200 vs. ≥200 ng/mL) | 1.985              | 1.316–2.994 | 0.001    |          |          | 0.331    |
| Tumor size (≥5 vs. ≤5 cm) | 4.750              | 2.927–7.709 | <0.001   | 2.947    | 1.621–5.359 | <0.001   |
| Tumor number (multifocal vs. unifocal) | 0.996              | 0.666–1.491 |          | 0.985    |          |          |
| Presence of PVT   | 3.907              | 2.589–5.896 | <0.001   |          |          | 0.365    |
| BCLC stage        | 0                  |          | <0.001   |          |          |          |
| A                 | 1.869              | 0.434–8.059 | 1.285    | 0.282–5.851 | 0.746    |
| B                 | 3.379              | 0.794–14.385 | 1.444    | 0.312–6.682 | 0.639    |
| C                 | 10.962             | 2.658–45.206 | 5.37     | 1.179–24.466 | 0.030    |
| Serum IGF-1 (ng/mL) | 0.995              | 0.990–0.999 | 0.019    | 0.995    | 0.989–1.000 | 0.043    |
| Serum VEGF (ng/mL) | 1.000              | 1.000–1.001 | 0.008    |          |          | 0.318    |
| mRECIST non-responder | 4.555             | 3.018–6.874 | <0.001   | 2.607    | 1.522–4.465 | <0.001   |

The hazard ratio was calculated by using the Cox proportional hazard model. 

APF = α-fetoprotein, BCLC = Barcelona Clinic Liver Cancer, HBV = hepatitis B virus, HCV = hepatitis C virus, mRECIST = modified Response Evaluation Criteria in Solid Tumors, NBNC = HBsAg- and ant-hepatitis C virus-negative, PVT = portal vein thrombosis.

doi:10.1371/journal.pone.0090862.t003

### Author Contributions

Conceived and designed the experiments: LJH. Performed the experiments: CEJ KHC. Analyzed the data: CEJ KHC. Contributed reagents/materials/analysis tools: YJJ CWM CYY LMJ CY LDH LYB YSJ KYJ YJH CJW KCY LHS. Wrote the paper: CEJ KHC LJH.
12. Mazziotti G, Sorvillo F, Mecore F, Carbone A, Rotondi M, et al. (2002) Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 95: 2539–2543.

13. Shao YY, Huang CC, Lin SD, Hsu CH and Cheng AI. (2012) Serum insulin-like growth factor-I levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 18: 3992–3997.

14. Cho EJ, Lee JH, Yu JI, Choi WM, Lee MJ, et al. (2013) Serum Insulin-Like Growth Factor-1 Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clin Cancer Res.

15. Lencioni R and Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease 30: 52–60.

16. Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, et al. (2013) Tranarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. Journal of vascular and interventional radiology : JVIR 24: 274–283.

17. Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58: 1101–1107.

18. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kash JS, et al. (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Annals of oncology : official journal of the European Society for Medical Oncology/European Society for Medical Oncology 24: 963–973.

19. Kim BK, Kim KA, Park JY, Ahn SH, Choi CY, et al. (2013) Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolization. European journal of cancer 49: 826–834.

20. Heagerty PJ, Lumley T and Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337–344.

21. Fluss R, Faraggi D and Reiser B (2005) Estimation of the Youden Index and its associated cutoff point. Biometrical journal Biometrische Zeitschrift 47: 450–472.

22. Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatu R, et al. (2012) Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. Journal of gastroenterology 47: 606–609.

23. Poon RT, Loo CP, Cheung ST, Yu WC and Fan ST (2003) Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer research 63: 3121–3126.

24. Kaseh AO, Abbruzzese JL, Vauthey JN, Abis A, Abdalla EK, et al. (2011) I-CLIP improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 80: 373–381.

25. Kaseh AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, et al. (2011) Clinical and prognostic implications of plasma insulin-like growth factor-I and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29: 3892–3899.

26. Castilla-Cortazar I, Garcia M, Maguerza B, Quiroga J, Perez R, et al. (1997) Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 113: 1682–1691.

27. Sobravals L, Rodriguez G, Romero-Tevejo JL, Goulet G, Monreal I, et al. (2010) Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 51: 912–921.

28. Conchillo M, de Kievt R, Payeas M, Quiroga J, Sangro R, et al. (2005) Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 43: 630–636.

29. Yang JD, Nakamura I and Roberts JR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Seminars in cancer biology 21: 35–43.

30. Hoshida Y, Villanueva A, Kobayashi M, Pex J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 359: 1995–2004.

31. Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16: 792–794.